Rescue Therapeutics Inc.
Reducing resistance to chemotherapy without added toxicity
This article was originally published in Start Up
Executive Summary
The founders of Rescue Therapeutics Inc. believe they have created a compound that can boost the power of widely used generic cancer drugs, including doxorubicin, without exposing a patient to any additional toxicity. Although RTI’s work with the compound was initially geared to testing it against non-Hodgkin's lymphoma, the start-up is taking it forward as a potential second-line treatment for ovarian cancer.